Editas Medicine, Inc. (EDIT)

2.24 0.05 (2.28%)

As of 2025-12-02 08:31:31 EST

Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

Traded asNasdaq: EDIT
ISINUS28106W1036
CIK0001650664
LEI5299000AON4Q9NT2JE42
EIN464097528
SectorBiotechnology
IndustryBiological Products, (No Diagnostic Substances)
CEOGilmore O'Neill
Employees226
Fiscal Year End1231
Address11 HURLEY ST., CAMBRIDGE, MA, 02141
Phone617-401-9000
Websitehttp://editasmedicine.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
EDITEditas Medicine, Inc.2025-12-02 08:31:312.240.052.28
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
EDIT0001650664Editas Medicine, Inc.US28106W10365299000AON4Q9NT2JE42464097528Nasdaq2836Biological Products, (No Diagnostic Substances)1231DE11 HURLEY ST.CAMBRIDGEMA02141UNITED STATESUS617-401-900011 HURLEY ST., CAMBRIDGE, MA, 0214111 HURLEY ST., CAMBRIDGE, MA, 02141—Biotechnology2013Gilmore O'Neill226http://editasmedicine.com383,847,15293,264,42197,618,660Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.2025-11-27 18:33:27
This is a preview of the latest data. Subscribe to access the full data.
EDIT Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
EDIT Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2024383,847,152-287,280,847-42.805782,976,2841,162,4341.4208
2023671,127,99937,321,3525.888481,813,85012,843,66218.622
2022633,806,647-513,529,526-44.758468,970,188451,2170.6585
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Baisong MeiChief Medical Officer, Executive Vice President2024492,327—75,332243,0008,900821,402
Erick LuceraChief Financial Officer, Executive Vice President2024482,600—350,176234,5448,2901,809,321
Gilmore O’NeillChief Executive Officer, President2024667,100—1,296,544440,2868,9005,126,868
Baisong MeiChief Medical Officer, Senior Vice President2023459,9300156,960186,9957,9801,141,405
Erick LuceraChief Financial Officer, Executive Vice President2023285,6150748,619146,0767942,215,616
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2024246
2023265
2022226
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue32,314,00078,123,00019,712,000
Cost Of Revenue———
Gross Profit———
Research And Development Expenses199,247,000177,651,000174,958,000
General And Administrative Expenses71,987,00069,653,00070,704,000
Operating Expenses283,466,000247,304,000245,662,000
Operating Income-251,152,000-169,181,000-225,950,000
Net Income-237,093,000-153,219,000-220,432,000
Earnings Per Share Basic-2.88-2.02-3.21
Earnings Per Share Diluted-2.88-2.02-3.21
Weighted Average Shares Outstanding Basic82,338,22075,965,63368,664,822
Weighted Average Shares Outstanding Diluted82,338,22075,965,63368,664,822
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents131,541,000123,652,000141,522,000
Marketable Securities Current138,372,000199,459,000202,752,000
Accounts Receivable16,266,00010,187,0005,145,000
Inventories———
Non Trade Receivables———
Other Assets Current———
Total Assets Current289,315,000340,829,000356,754,000
Marketable Securities Non Current0104,024,00093,097,000
Property Plant And Equipment14,497,00012,032,00015,569,000
Other Assets Non Current5,223,0008,588,0005,253,000
Total Assets Non Current52,274,000158,324,000157,567,000
Total Assets341,589,000499,153,000514,321,000
Accounts Payable5,493,0008,269,0009,511,000
Deferred Revenue6,221,0008,221,0008,221,000
Short Term Debt5,000,000——
Other Liabilities Current45,859,00034,563,00031,296,000
Total Liabilities Current77,225,00063,217,00060,110,000
Long Term Debt57,434,000——
Other Liabilities Non Current3,072,0001,800,000—
Total Liabilities Non Current130,090,00086,839,00093,531,000
Total Liabilities207,315,000150,056,000153,641,000
Common Stock8,0008,0007,000
Retained Earnings-1,468,443,000-1,231,350,000-1,078,131,000
Accumulated Other Comprehensive Income268,000198,000-3,601,000
Total Shareholders Equity134,274,000349,097,000360,680,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization5,809,0006,064,0006,337,000
Share Based Compensation Expense21,417,00019,798,00029,294,000
Other Non Cash Income Expense415,000-1,596,000724,000
Change In Accounts Receivable6,079,0005,042,0004,878,000
Change In Inventories———
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable-2,286,000-1,492,0004,368,000
Change In Other Liabilities1,271,0001,800,00010,505,000
Cash From Operating Activities-210,284,000-132,178,000-177,349,000
Purchases Of Marketable Securities86,217,000258,517,000315,186,000
Sales Of Marketable Securities257,189,000259,505,000433,354,000
Acquisition Of Property Plant And Equipment8,826,0004,719,0004,118,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities162,146,000-3,731,000114,068,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends000
Issuance Of Common Stock0117,079,000979,000
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities56,027,000118,039,0001,284,000
Change In Cash7,889,000-17,870,000-61,997,000
Cash At End Of Period131,541,000123,652,000141,522,000
Income Taxes Paid———
Interest Paid———
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share-2.88-2.02-3.21
Price To Earnings Ratio-0.441-5.0149-2.7632
Earnings Growth Rate42.5743-37.071712.6316
Price Earnings To Growth Ratio-0.01040.1353-0.2188
Book Value Per Share1.63084.59555.2528
Price To Book Ratio0.77882.20431.6886
Ebitda-229,156,000-147,155,000-214,095,000
Enterprise Value35,462,539.4——
Dividend Yield000
Dividend Payout Ratio000
Debt To Equity Ratio0.465——
Capital Expenditures8,274,0002,527,0004,788,000
Free Cash Flow-218,558,000-134,705,000-182,137,000
Return On Equity-1.7657-0.4389-0.6112
One Year Beta1.88851.72792.1949
Three Year Beta2.04172.03481.5786
Five Year Beta1.60911.64051.6516
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
O'Neill Gilmore NeilDirector, CEO2025-09-035,592D274,690
Parison AmySVP, Chief Financial Officer2025-09-03458D16,369
Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER2025-09-03710D69,490
Parison AmySVP, Chief Financial Officer2025-08-07679D16,827
Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER2025-07-315,121D64,398
This is a preview of the latest data. Subscribe to access the full data.
Senate Trading
Name Of Reporting PersonType Of Reporting PersonReport DateTransaction TypeTransaction DateOwner TypeAmount
James M InhofeSenator2019-12-20Sale (Full)2019-02-04Self$15,001 - $50,000
James M InhofeSenator2019-02-25Sale (Full)2019-02-04Self$15,001 - $50,000
James M InhofeSenator2017-11-08Purchase2017-10-19Self$15,001 - $50,000
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Daniel Goldman2023-05-19NY10Sale2023-04-10—$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Strategic Advocates LLC2025-09-303,7371,0773.4698
JPMORGAN CHASE & CO2025-09-302,847,715820,6673.47
CIBC Private Wealth Group LLC2025-09-3025,3317,3003.47
Wilmington Savings Fund Society, FSB2025-09-303,4701,0003.47
Sunbelt Securities, Inc.2025-09-30312903.4667
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
RYDEX SERIES FUNDS2025-09-30Class CRYCMX118409.460.0061
RYDEX SERIES FUNDS2025-09-30Class ARYAKX118409.460.0061
RYDEX SERIES FUNDS2025-09-30Class HRYMKX118409.460.0061
RYDEX SERIES FUNDS2025-09-30Class HRYRHX198687.060.0055
RYDEX SERIES FUNDS2025-09-30Class CRYROX198687.060.0055
This is a preview of the latest data. Subscribe to access the full data.